A Phase 2 Study Of Poziotinib In Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens For MBC
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
This is a Phase 2, open-label, multicenter study to establish the dose regimen and evaluate the preliminary efficacy and the safety / tolerability of poziotinib in patients with HER2-positive MBC who have received at least two (2), but no more than four ( 4) prior HER2-directed treatment regimens including trastuzumab and T-DMI. The Screening period (Day -30 to Day -1) lasts up to approximately thirty (30) days prior to Cycle 1, Day 1. Patients must meet all Inclusion/Exclusion Criteria to participate in the study. Eligible patients will provide written Informed Consent prior to undergoing any study procedures. Each treatment cycle is twenty one (21) calendar days in duration.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.